Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B
被引量:8
摘要
Background and Aims: Chronic hepatitis B virus(HBV)in-fection remains a major public health problem globally.Here,we describe the baseline characteristics and treatment pro-files of HBV-infected patients recruited to the China Registry of Hepatitis B.Methods: Inclusion criteria were patients with different stages of chronic HBV infection and complete key data.Exclusion criteria were patients with hepatocellular car-cinoma.The baseline clinical,laboratory and treatment pro-files were analyzed.Results: Finally,40,431 patients were included.The median age was 43 years,with 65.2%being men and 51.3%being positive for hepatitis B e antigen(HBeAg).The most common initial diagnosis was chronic hep-atitis B(81.0%),followed by cirrhosis(9.3%),inactive carrier of hepatitis B surface antigen(HBsAg)(6.7%),and immune tolerant phase of hepatitis B infection(3.0%).Among the 21,228 patients who were on treatment,88.0%,10.0%and 2.0%received nucleos(t)ide analogues(NAs),interferon or combination of NAs and interferon,respectively.The propor-tion of patients who received preferred NAs(entecavir or te-nofovir disoproxil fumarate)had increased from 13.5%in 2003 to 79.7%in 2016.Conclusions: We concluded that middle-aged men accounted for most of the patients with chronic hepatitis B in this cross-sectional study.About half of the patients were HBeAg-positive.NAs were the most com-monly used therapy,and use of the preferred NAs had steadily increased in the past decade.
参考文献1
-
1Lai Wei,Ji-Dong Jia,Xin-Hua Weng,Xiao-Guang Dou,Jia-Ji Jiang,Hong Tang,Qin Ning,Qing-Qing Dai,Run-Qin Li,Jie Liu.Treating chronic hepatitis B virus:Chinese physicians' awareness of the 2010 guidelines[J].World Journal of Hepatology,2016,8(18):762-769. 被引量:4
二级参考文献16
-
1Chinese Society of Hepatology,Chinese Medical Association and Chinese Society of Infectious Diseases,Chinese Medical Association.Guideline on prevention and treatment of chronic hepatitis B in China (2005)[J].Chinese Medical Journal,2007(24):2159-2173. 被引量:42
-
2European Association for the Study of the Liver.EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection[J]. Journal of Hepatology . 2012 (1)
-
3Xiaofeng Liang,Shengli Bi,Weizhong Yang,Longde Wang,Gang Cui,Fuqiang Cui,Yong Zhang,Jianhua Liu,Xiaohong Gong,Yuansheng Chen,Fuzhen Wang,Hui Zheng,Feng Wang,Jing Guo,Zhiyuan Jia,Jingchen Ma,Huaqing Wang,Huiming Luo,Li Li,Shuigao Jin,Stephen C. Hadler,Yu Wang.Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination[J].Vaccine.2009(47)
-
4Sang Hoon Ahn,Henry L. Y. Chan,Pei-Jer Chen,Jun Cheng,Mahesh K. Goenka,Jinlin Hou,Seng Gee Lim,Masao Omata,Teerha Piratvisuth,Qing Xie,Hyung Joon Yim,Man-Fung Yuen.Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions[J].Hepatology International.2010(1)
-
5Uchenna H. Iloeje,Hwai–I. Yang,Jun Su,Chin–Lan Jen,San–Lin You,Chien–Jen Chen.Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load[J]. Gastroenterology . 2006 (3)
-
6Anna S. F. Lok,Brian J. McMahon.??Chronic hepatitis B: Update 2009(J)Hepatology . 2009 (3)
-
7Yun-Fan Liaw,Jia-Horng Kao,Teerha Piratvisuth,Henry Lik Yuen Chan,Rong-Nan Chien,Chun-Jen Liu,Ed Gane,Stephen Locarnini,Seng-Gee Lim,Kwang-Hyub Han,Deepak Amarapurkar,Graham Cooksley,Wasim Jafri,Rosmawati Mohamed,Jin-Lin Hou,Wan-Long Chuang,Laurentius A.L.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012 update. Hepatol Int . 2012
-
8Chen Chien-Jen,Yang Hwai-I,Su Jun,Jen Chin-Lan,You San-Lin,Lu Sheng-Nan,Huang Guan-Tarn,Iloeje Uchenna H.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA : the journal of the American Medical Association . 2006
-
9Chao Jonathan,Chang Ellen,So Samuel.Hepatitis B and liver cancer knowledge and practices among healthcare and public health professionals in China: a cross-sectional study. BMC Public Health . 2010
-
10Lin-Hong Ning,Jia Hao,Zhong-Li Liao,Yuan-Yuan Zhou,Hong Guo,Xiao-Yan Zhao.??A survey on the current trends in the management of hepatitis B in China(J)European Journal of Gastroenterology & Hepatology . 2012 (8)
共引文献3
-
1吴晓宁,张伟,周家玲,王麟,孙亚朦,孟彤彤,王晓明,尤红,欧晓娟,贾继东.基线HBV DNA水平对代偿期乙型肝炎肝硬化患者抗病毒治疗后临床转归的影响[J].临床肝胆病杂志,2018,34(8):1678-1682. 被引量:5
-
2黄超,杜亮,陈耀龙,王小琴,蒋帅,李俊,蒋庭德,吕鹏,王强.中国医务人员对临床实践指南的使用和需求调查[J].中国循证医学杂志,2019,19(6):635-638. 被引量:14
-
3孔媛媛,魏巍,单姗,马红,欧晓娟,徐小元,段钟平,侯金林,魏来,尤红,贾继东,中国消除乙肝临床科研平台(CR-HepB)研究组.乙型肝炎肝硬化患者的临床特征与抗病毒治疗模式变化[J].肝脏,2020,25(2):123-127. 被引量:24
同被引文献38
-
1周雪宁,万延川,权志博.性别对乙肝血清标志物模式人群分布率的影响及其探讨[J].实用医技杂志,2008,15(14):1802-1803. 被引量:10
-
2赖玮婧,刘芳,付平.慢性肾脏病评估及管理临床实践指南解读——从K/DOQI到KDIGO[J].中国实用内科杂志,2013,33(6):448-453. 被引量:206
-
3毛向群,熊小庆,涂秋凤,余平,杨健平.江西省乙型肝炎发病趋势的时间序列和预测模型分析[J].中国预防医学杂志,2013,14(6):435-438. 被引量:8
-
4中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组,李兰娟,韩涛.肝衰竭诊治指南(2018年版)[J].中华肝脏病杂志,2019,27(1):18-26. 被引量:413
-
5沈忠周,王雅文,马帅,赵鹏宇,于凯,严宝湖,江宇.ARIMA模型在预测我国乙肝月报告发病数中的应用[J].中华疾病控制杂志,2018,22(3):298-301. 被引量:18
-
6颜成果,姚云清,毛晓琴.恩替卡韦治疗慢性乙型肝炎病毒携带者近期疗效观察[J].中华肝脏病杂志,2014,22(12):900-903. 被引量:13
-
7慢性乙型肝炎防治指南(2015更新版)[J].中华肝脏病杂志,2015,23(12):888-905. 被引量:680
-
8王贵强,王福生,成军,任红,庄辉,孙剑,李兰娟,李杰,孟庆华,赵景民,段钟平,侯金林,贾继东,唐红,盛吉芳,彭劼,鲁凤民,谢青,魏来.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960. 被引量:1071
-
9龙琴,姚云清,颜成果.慢性乙型肝炎病毒携带者抗病毒治疗必要性的研究进展[J].中华肝脏病杂志,2016,24(6):465-468. 被引量:9
-
10黄淑琼,陈红缨,蔡晶,杨雯雯.应用ARIMA模型分析湖北省乙型病毒性肝炎时间分布特征[J].公共卫生与预防医学,2016,27(4):14-18. 被引量:9
引证文献8
-
1洪晓绿,徐沛演,潘小平.CYP2E1和CYP1A1基因型与广州北部地区人群HBV易感性间的相关性分析[J].肝脏,2021,26(2):131-135. 被引量:2
-
2李敏,苏健婷,武珊珊,韦在华,孔媛媛,贾继东.乙型肝炎肝硬化患者年龄和性别与肝病相关死亡风险的关系[J].中华肝脏病杂志,2021,29(5):403-408. 被引量:10
-
3邓子德.替诺福韦在慢性乙型肝炎患者核苷(酸)类似物转换治疗中的应用[J].中国新药与临床杂志,2021,40(10):678-683. 被引量:4
-
4周瑜,李明珂,汤艳.2009-2019年泸州市乙型肝炎流行病学特征及其预测[J].西南医科大学学报,2021,44(6):659-664. 被引量:4
-
5祝胜郎,肖光明,韩亚娟,雷鸣,关玉娟.慢性乙型肝炎病毒感染者合并肾、骨损伤的风险及临床管理探讨[J].肝脏,2022,27(1):113-116. 被引量:1
-
6何建,姚云清,夏仁祥,邱天霁,龙玲,汪燕,蒋影.恩替卡韦治疗HBeAg阳性慢性乙型肝炎病毒携带者PD-1^(+)CXCR5^(+)CD4^(+)T淋巴细胞和sPD-1水平观察[J].中华肝脏病杂志,2022,30(3):316-322. 被引量:1
-
7王皓,单姗,尤红,徐小元,魏来,侯金林,庄辉,孔媛媛,贾继东,中国消除乙肝临床研究平台(CR-HepB)研究组.抗病毒治疗适应证变化对提高慢性乙型肝炎治疗率的影响[J].临床肝胆病杂志,2022,38(6):1269-1274. 被引量:10
-
8贾继东.我国慢性乙型肝炎防控所取得的成就与未来挑战[J].中国临床医生杂志,2022,50(10):1135-1136. 被引量:1
二级引证文献31
-
1张云颖,关霞,任小平.病毒性肝炎-肝硬化-原发性肝癌病因形态学及防治策略的研究进展[J].癌症进展,2021,19(17):1745-1748. 被引量:15
-
2吴瑛,王涛.慢性乙型病毒性肝炎流行病学特征及影响因素分析[J].现代实用医学,2022,34(5):686-687. 被引量:4
-
3周晓玲,姚迪.恩施地区吸烟人群P450和GST基因多态性与肺癌易感性研究[J].国际检验医学杂志,2022,43(17):2152-2155. 被引量:1
-
4贾继东.我国慢性乙型肝炎防控所取得的成就与未来挑战[J].中国临床医生杂志,2022,50(10):1135-1136. 被引量:1
-
5王辉.恩替卡韦与替诺福韦酯治疗高病毒载量慢性乙型肝炎患者的临床效果分析[J].系统医学,2022,7(16):100-103. 被引量:1
-
6冯艳,缪应祥,陈敏.替诺福韦联合异甘草酸镁对CHB患者肝功能与免疫系统的影响及药学评价[J].中国处方药,2022,20(11):99-101.
-
7孙建生,汪进洋,吴婷婷.2012—2020年东营市东营区乙型病毒性肝炎流行病学特征[J].职业卫生与病伤,2022,37(5):283-287.
-
8吴颖.替诺福韦酯对慢性乙型肝炎患者免疫功能及肝功能的影响[J].中国当代医药,2022,29(35):53-56. 被引量:1
-
9冯颖,时克,王宪波.肝硬化合并肠系膜上静脉栓塞患者2年预后预测模型的构建与验证[J].首都医科大学学报,2023,44(1):107-114. 被引量:1
-
10宇汝胜,童钟,段胜,王晓刚,郑吉顺,胡启立.前S1抗原与乙型肝炎表面抗原比值预测乙型肝炎病毒相关肝硬化病人肝癌发生风险的价值分析[J].临床外科杂志,2022,30(11):1044-1047.
-
1Lun-Gen Lu.Antiviral Therapy of Liver Cirrhosis Related to Hepatitis B Virus Infection[J].Journal of Clinical and Translational Hepatology,2014,2(3):197-201. 被引量:11
-
2Stefano D'Errico,Diana Bonuccelli,Margherita Neri.Post-coital death in chronic sildenafil abuser[J].Journal of Geriatric Cardiology,2020,17(3):169-172.
-
3Chencheng Xie,Yong-Fang Kuo,Ashwani K.Singal.Changing Population of Liver Transplant Recipients in the Era of Direct-acting Antiviral Therapy[J].Journal of Clinical and Translational Hepatology,2020,8(3):262-266.
-
4Anais Brayette,Marie Essig,Paul Carrier,Marilyne Debette-Gratien,Anais Labrunie,Sophie Alain,Marianne Maynard,Nathalie Ganne-Carrie,Eric Nguyen-Khac,Pauline Pinet,Victor De Ledinghen,Christophe Renou,Philippe Mathurin,Claire Vanlemmens,Vincent Di Martino,Anne Gervais,Juliette Foucher,Fouchard-Hubert Isabelle,Julien Vergniol,Isabelle Hourmand-Ollivier,Daniel Cohen,Xavier Duval,Thierry Poynard,Marc Bardou,Armand Abergel,Manh-Thong Dao,Thierry Thevenot,Jean-Baptiste Hiriart,Valerie Canva,Guillaume Lassailly,Christine Aurières,Nathalie Boyer,Dominique Thabut,Pierre-Henri Bernard,Matthieu Schnee,Dominique Larrey,Bertrand Hanslik,Severine Hommel,Jeremie Jacques,Veronique Loustaud-Ratti.Subclinical proximal tubulopathy in hepatitis B:The roles of nucleot(s)ide analogue treatment and the hepatitis B virus[J].World Journal of Hepatology,2020,12(12):1326-1340. 被引量:1
-
5Prashika Singh,Dylan Kairuz,Patrick Arbuthnot,Kristie Bloom.Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach[J].World Journal of Gastroenterology,2021,27(23):3182-3207. 被引量:2
-
6Xiao-Fan Chen,Ya-Nan Fan,Chong-Wen Si,Yan-Yan Yu,Jia Shang,Zu-Jiang Yu,Qing Mao,Qing Xie,Wei Zhao,Jun Li,Zhi-Liang Gao,Shan-Ming Wu,Hong Tang,Jun Cheng,Xin-Yue Chen,Wen-Hong Zhang,Hao Wang,Zhong-Nan Xu,Ling Wang,Jun Dai,Jing-Hang Xu.Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients:Results of a multicenter,double-blind,double-dummy,clinical trial at 96 weeks[J].World Journal of Clinical Cases,2021,9(18):4690-4699. 被引量:1
-
7Haijun Li,Tianyang Li,Ian Nicholas Crispe,Zhengkun Tu.HCV immune evasion and regulatory T cell activation: cause or consequence?[J].Cellular & Molecular Immunology,2018,15(5):536-538.
-
8Lillian Lou.Advances in Nucleotide Antiviral Development from Scientific Discovery to Clinical Applications:Tenofovir Disoproxil Fumarate for Hepatitis B[J].Journal of Clinical and Translational Hepatology,2013,1(1):33-38.
-
9Yong Lin,Jun Yuan,Quanxin Long,Jieli Hu,Haijun Deng,Zhenyu Zhao,Juan Chen,Mengji Lu,Ailong Huang.Patients with SARS-CoV-2 and HBV coinfection are at risk of greater liver injury[J].Genes & Diseases,2021,8(4):484-492. 被引量:6
-
10Vladimir Dugalic,Igor I Ignjatovic,Jelena Djokic Kovac,Nikola Ilic,Jelena Sopta,Slavenko R Ostojic,Dragan Vasin,Marko D Bogdanovic,Igor Dumic,Tamara Milovanovic.Low-grade fibromyxoid sarcoma of the liver: A case report[J].World Journal of Clinical Cases,2021,9(1):175-182. 被引量:1